o(6)-benzylguanine has been researched along with irinotecan in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Coffman, BL; Green, MD; Iyer, L; King, CD; Ratain, MJ; Roy, SK; Tephly, TR; Whitington, PF | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Billups, CA; Danks, MK; McLendon, RE; Wagner, LM; Weiss, BD; Yoon, KJ | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Chen, WH; Hindle, A; Koneru, B; Lopez-Barcons, L; Makena, MR; Nguyen, TH; Reynolds, CP | 1 |
1 review(s) available for o(6)-benzylguanine and irinotecan
| Article | Year |
|---|---|
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
1 trial(s) available for o(6)-benzylguanine and irinotecan
| Article | Year |
|---|---|
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Disease-Free Survival; Female; Glioma; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2009 |
4 other study(ies) available for o(6)-benzylguanine and irinotecan
| Article | Year |
|---|---|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Causality; Crigler-Najjar Syndrome; Glucuronosyltransferase; Guanine; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Nitrophenols; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Uridine Diphosphate; Zidovudine | 1998 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Irinotecan; Mice; Mice, SCID; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neuroblastoma; Nuclear Proteins; Temozolomide; Tumor Suppressor Proteins | 2007 |
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Irinotecan; Mice; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Real-Time Polymerase Chain Reaction; RNA, Messenger; Temozolomide; Up-Regulation | 2021 |